GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tricida Inc (OTCPK:TCDAQ) » Definitions » 10-Year RORE %

Tricida (Tricida) 10-Year RORE % : 0.00% (As of Sep. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Tricida 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Tricida does not have enough data to calculate 10-Year RORE %.


Tricida 10-Year RORE % Historical Data

The historical data trend for Tricida's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tricida 10-Year RORE % Chart

Tricida Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
10-Year RORE %
Get a 7-Day Free Trial - - - - -

Tricida Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tricida's 10-Year RORE %

For the Biotechnology subindustry, Tricida's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tricida's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tricida's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Tricida's 10-Year RORE % falls into.



Tricida 10-Year RORE % Calculation

Tricida's 10-Year RORE % for the quarter that ended in Sep. 2022 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2022 and 10-year before.


Tricida  (OTCPK:TCDAQ) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Tricida 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Tricida's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tricida (Tricida) Business Description

Traded in Other Exchanges
N/A
Address
7000 Shoreline Court, Suite 201, South San Francisco, CA, USA, 94080
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.
Executives
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert J Alpern director YALE SCHOOL OF MEDICINE, 333 CEDAR STREET, C203 SHM, NEW HAVEN CT 06520
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Sibling Capital Fund Ii-b L.p. 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Ii Llc 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Brian M. Isern 10 percent owner, other: *possible member of 10% group 2033 6TH AVE., SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-c L.p. 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Ventures Iii Llc 10 percent owner, other: *possible member of 10% group 2033 6TH AVE, SUITE 330, SEATTLE WA 98121
Sibling Capital Fund Ii-a L.p. 10 percent owner, other: possible member of 10% group 500 YALE AVE N, SEATTLE WA 98109
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036